Cambridge, Mass., USA - June 5, 2014, Cambridge, Mass., USA - Ironwood Pharmaceuticals, Inc. announced the appointment of Douglas Williams to its board of directors.
Article continues below
Dr. Williams currently serves as executive vice president, research and development for Biogen Idec Inc. and was previously chief executive officer of ZymoGenetics, Inc. Dr. Williams has served as executive vice president, research and development at Biogen Idec since January 2011.
Previously, he held several senior executive positions, including chief executive officer and chief scientific officer, at ZymoGenetics, where he also served as a director. While at ZymoGenetics, he oversaw development of peginterferon lambda-1a, now in Phase III, and several other oncology and immunology programs.
Before joining ZymoGenetics, Dr. Williams served as chief scientific officer and executive vice president of research and development at Seattle Genetics Inc., where he oversaw the development of cancer drug Adcetris (brentuximab vedotin). Before that he held a series of scientific and senior leadership positions over a decade at Immunex Corp., where he led development of blockbuster rheumatoid arthritis drug Enbrel (etanercept).
Dr. Williams' tenure at Immunex culminated with his position as executive vice president and chief technology officer, and he went on to serve as a senior vice president at Amgen Inc. following its acquisition of Immunex.
Before joining industry, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York. He serves on the board of directors of Regulus Therapeutics Inc., and previously served on the board of directors of Oncothyreon Inc. and Array BioPharma Inc. ■
A hyperactive weather pattern will bring an expansive low pressure system across mainland U.S., resulting in widespread impactful weather to progress from west to east across the country through the next few days.